Among patients with IDH mutant gliomas with TP53 mutations, the median PFS was 31 months for gliomas harboring any one of +8q, −9p, −11p, or +12p compared with 47 months for patients harboring all other CNAs (n = 24; p = 0.067). This evidence concerns the gene TP53 and central nervous system cancer.